13 results about "Genus staphylococcus" patented technology

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

To provide a detection method capable of rapidly detecting drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas; a method for providing an index for selecting an antimicrobial agent for bacteria; and a primer set usable in these methods.SOLUTION: The detection method for drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas according to the present disclosure comprises a step of performing nucleic acid amplification of target genes (1) to (3) and (4) below for a target sample, and detecting drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas in the sample: (1) the mecA gene; (2) the spa gene of Staphylococcus aureus; (3) the tuf gene and / or the rpoB gene of bacteria of the genus Staphylococcus; and (4) the 16S rRNA gene of bacteria of the genus Pseudomonas.SELECTED DRAWING: Figure 1

The invention discloses a staphylococcus saprophyticus NCSL-YWH2, and the preservation number of the staphylococcus saprophyticus NCSL-YWH2 is CGMCC (China General Microbiological Culture Collection Center) No.35847. The staphylococcus saprophyticus NCSL-YWH2 has the advantages that the staphylococcus saprophyticus The invention also discloses a culture method of the staphylococcus saprophyticus NCSL-YWH2 and an application of the staphylococcus saprophyticus NCSL-YWH2 in enriching a lithium element in a lithium-containing liquid. The staphylococcus saprophyticus NCSL-YWH2 disclosed by the invention is a staphylococcus microorganism which is reported for the first time and has the capability of enriching lithium ions from a lithium-containing liquid. The strain can be widely applied to lithium extraction of salt lake brine, unconventional lithium-containing water resources and various lithium-containing industrial wastewater, efficient enrichment and concentration of lithium ions can be realized by utilizing the strain, and a biological method has the characteristics of greenness and low carbon.

Disclosed herein are methods and systems for detecting microorganisms in a sample and the use of such methods for selecting and monitoring therapies. The specificity of an indicator bacteriophage, such as a Staphylococcus specific bacteriophage, allows the detection of a particular microorganism, such as Staphylococcus, and the indicator signal can be amplified to optimize assay sensitivity.

Described herein is an extract of a herbal composition comprising at least two different dry plants, the compounds are useful as antimicrobial and / or antibiotic film agents in the treatment or prevention of microbial infections caused by bacteria (e.g., Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus, or Staphylococcus) or by fungi, as well as in the treatment or prevention of microbial infections caused by bacteria (e.g., Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus, or Staphylococcus). It has been found that in such an extract, the active ingredients exert their biological effects in a synergistic manner. The extracts may form active ingredients of food supplements, nutraceuticals, pharmaceutical or cosmetic compositions or functional foods or food additives. Also described herein are methods for preparing the extracts.

Disclosed here are phage compositions for infecting and / or killing Staphylococcus spp.

This application provides a *Staphylococcus pseudoci* AT8 strain for degrading antibiotics and its application. The *Staphylococcus pseudoci* is a species of Staphylococcus (…). Staphylococcus The *Staphylococcus pseudocarpa* species, having a 16S rDNA sequence as shown in SEQ ID NO:1, is named... Staphylococcus pseudoxylosus AT8, deposited on November 20, 2025 at the Guangdong Provincial Center for Microbial Culture Collection, accession number: GDMCC No: 67323. This application pertains to *Staphylococcus pseudocarpa*. Staphylococcus pseudoxylosus AT8 can achieve a degradation rate of over 90% for trimethoprim and tilmicosin, and over 78% for enrofloxacin. Furthermore, this application enriches the antibiotic-degrading bacterial strain library, promotes the control of new antibiotic pollutants in livestock and poultry manure and farmland soil, and facilitates the resource-based treatment and safe utilization of solid waste, demonstrating broad application prospects.

Provided are a method for enhancing the immunogenicity of a recombinant protein antigen and use thereof. The method comprises conjugating a polysaccharide with a recombinant protein antigen to form a nano-scale protein antigen. The polysaccharide is selected from sodium hyaluronate, chitosan, glucan, fucoidan, and sodium alginate. The recombinant protein antigen is a protein antigen derived from a bacterium. The bacterium belongs to the genus of Staphylococcus, Neisseria, Klebsiella, Escherichia, Clostridium, Salmonella, Shigella, Pseudomonas, Acinetobacter, Bordetella, Enterococcus, Haemophilus, Mycobacterium, or Streptococcus. The method not only improves the immunogenicity of the recombinant protein antigen, but also overcomes the defects of competitive immunoregulation and poor immune enhancement effects caused by bacterial capsular polysaccharide modification. The method also has the advantages of high clinical application value, simple starting material acquisition, low cost, good process stability, ease in scale expansion, high safety, and the like.

The application discloses application of Qijiao Shengbai capsules in preparation of medicines for regulating intestinal microorganism flora disorder. The Qijiao Shengbai capsule is composed of Xue Renshen, Huangqi, Ajiao, Danggui, Da Zao, Ku Shen and Yinyanghe. By using the Qijiao Shengbai capsule, the microorganism flora is increased in the level of Firmicutes, increased in the level of Proteobacteria, reduced in the level of Bacteroidetes, reduced in the level of Akkermansia muciphila, and reduced in the level of Actinobacteria; in the level of genus, the microorganism flora is increased in the level of Prevotella, increased in the level of Lactobacillus, increased in the level of Parabacteroides, reduced in the level of Bacteroides, reduced in the level of Enterobacter, and reduced in the level of Staphylococcus, so as to regulate the intestinal microorganism flora. The application provides a new idea for research and development of medicines for preventing and treating intestinal flora disorder.

[Problem] To provide a novel composition having gut microbiota regulating effect. [Solution] A composition for regulating gut microbiota, the composition being characterized by containing a sulfated polysaccharide that induces gut bacteria interactions in a host and alters the profile of the microbiota so that bacteria contributing to improving the host's health proliferate and pathogens are suppressed. The sulfated polysaccharide is preferably rhamnan sulfate. It is also preferable that the gut microbiota regulation (1) augments at least one selected from the group consisting of Prevotellaceae UCG-001, the Clostridia vadinBB60 group, and Mucispirillum schaedleri and (2) decreases at least one selected from the group consisting of the Rikenellaceae RC9 gut group, ASF356, and Staphylococcus.

Disclosed are compositions, devices, kits, and methods for prevention and / or treatment of Staphylococcus infection. In specific embodiments, Staphylococcus are S. pseudintermedius and / or S. aureus. Aspects of the present disclosure can be directed to bacteriophage compositions comprising one or more of vB_SpsM-DH2, vB_SpsS-DH5, and / or vB_SpsM-DS10. Further disclosed are devices and kits comprising such compositions, and methods for use of such compositions in treatment and prevention of pathogenic Staphylococcus infection.

Naphthoquinone derivatives have anti-inflammatory, antifungal and antibacterial effects. The naphthoquinone derivatives are able to effectively inhibit expression of inflammatory factors and be used for treating infections caused by Candida and Staphylococcus. In addition, an anti-inflammatory method is provided which includes administering the naphthoquinone derivatives for treatment, and a method of treating microbial infection includes administering the naphthoquinone derivatives for treatment.

Methods for identifying an individual having a predisposition to developing acne, for assessing severity of acne lesions, and for personalized prevention, diagnosis, and treatment of acne are disclosed. The methods include: (a) obtaining microbiome sample from skin of an individual; (b) determining an amount of one or more bacteria in the microbiome sample, wherein the one or more bacteria are selected from Lawsonella, Cutibacterium, Staphylococcus, Corynebacterium, Streptococcus, Micrococcus, and Neisseriaceae; (c) comparing the amount of the one or more bacteria to a control; and (d) identifying a difference between the amount of the one or more bacteria in the microbiome sample and the control.